Overview
NuCana is a clinical-stage biopharmaceutical engaged in the development of drugs that could improve the way chemotherapy treatments fight cancer. Its proprietary technology, ProTide, is being studied for its ability to transform nucleoside analogs into more effective and more easily tolerated chemotherapy agents. The company's two lead candidates, Acelarin and NUC-3373, are in clinical tests for the treatment of solid tumors. Another ProTide
...
Read More candidate, NUC-7738, is in pre-clinical evaluation. NuCana holds the global commercialization rights for all of its candidates. The ProTide technology was developed at Cardiff University by the late Dr. Christopher McGuigan. NuCana went public in September 2017.
Read Less
Read More candidate, NUC-7738, is in pre-clinical evaluation. NuCana holds the global commercialization rights for all of its candidates. The ProTide technology was developed at Cardiff University by the late Dr. Christopher McGuigan. NuCana went public in September 2017.
Read Less
Hugh Stephen Griffith
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Estimated
?
Estimated
$1.56 million
Actual
$14
?
?
Contacts
Get in Touch with 7 Principals* and 25 Contacts
-
Hugh Stephen GriffithDirector
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue
$1.56 million
USD
Modelled
1 USD = 0.7331 GBP
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$26 | -$36 | -$32 |
| Net Investing Cash | $0 | $4 | $0 |
| Net Financing Cash | $11 | -$0 | -$0 |
| Net Change in Cash | -$15 | -$32 | -$32 |
| Cash at Beginning of Period | $23 | $57 | $82 |
| Cash at End of Period | $9 | $23 | $57 |
| Capital Expenditure | -$0 | -$1 | -$1 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $9 | $23 | $57 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $8 | $11 | $18 |
| Asset Summary | |||
| Total Current Assets | $17 | $34 | $75 |
| Tangible Fixed Assets | $0 | $1 | $1 |
| Intangible Assets | $3 | $3 | $3 |
| Total Assets | $15 | $28 | $58 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $4 | $5 | $7 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $8 | $13 | $20 |
| Liability Summary | |||
| Total Current Liabilities | $12 | $17 | $26 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $12 | $18 | $27 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $8 | $3 | $3 |
| Retained Earnings | -$306 | -$283 | -$246 |
| Equity Summary | |||
| Total Equity | $8 | $20 | $53 |
| Shares Outstanding | 141,537,199 | 52,360,335 | 51,872,887 |